Pharmacological exposure to ribavirin: a key player in the complex network of factors implicated in virological response and anaemia in hepatitis C treatment.

[1]  G. Dusheiko,et al.  P70 Telaprevir in combination with peginterferon and ribavirin in genotype 1 HCV Treatment-Naïve patients: final results of phase 3 ADVANCE Study , 2011, Gut.

[2]  G. Norkrans,et al.  Ribavirin plasma concentration is a predictor of sustained virological response in patients treated for chronic hepatitis C virus genotype 2/3 infection , 2011, Journal of viral hepatitis.

[3]  T. Berg,et al.  Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. , 2011, Journal of hepatology.

[4]  Yusuke Nakamura,et al.  Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir , 2011, Hepatology.

[5]  A. Casrouge,et al.  Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV. , 2011, The Journal of clinical investigation.

[6]  K. Shianna,et al.  Quantitation of pretreatment serum interferon‐γ–inducible protein‐10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response , 2011, Hepatology.

[7]  D. Ge,et al.  Hepatitis C trials that combine investigational agents with pegylated interferon should be stratified by interleukin‐28B genotype , 2010, Hepatology.

[8]  P. Siersema,et al.  Suboptimal endogenous erythropoietin response in chronic hepatitis C patients during ribavirin and PEG interferon treatment , 2010, European journal of gastroenterology & hepatology.

[9]  William M. Lee,et al.  Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate. , 2010, Gastroenterology.

[10]  V. Soriano,et al.  Influence of a single nucleotide polymorphism at the main ribavirin transporter gene on the rapid virological response to pegylated interferon-ribavirin therapy in patients with chronic hepatitis C virus infection. , 2010, The Journal of infectious diseases.

[11]  K. Shianna,et al.  Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. , 2010, Gastroenterology.

[12]  K. Shianna,et al.  An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. , 2010, Gastroenterology.

[13]  E. Schiff,et al.  Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial , 2010, The Lancet.

[14]  G. Duverlie,et al.  Ribavirin Monitoring in Chronic Hepatitis C Therapy: Anaemia versus Efficacy , 2010, Antiviral therapy.

[15]  X. Lao,et al.  Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. , 2010, Gastroenterology.

[16]  R. MAC NICHOLAS,et al.  Review article: optimizing SVR and management of the haematological side effects of peginterferon/ribavirin antiviral therapy for HCV – the role of epoetin, G‐CSF and novel agents , 2010, Alimentary pharmacology & therapeutics.

[17]  M. Carbone,et al.  Plasma/erythrocyte ribavirin x100 ratio as an indicator of sustained virological response in HCV genotype 1 patients with early virological response , 2010, Antiviral therapy.

[18]  M. Manns,et al.  Telaprevir for previously treated chronic HCV infection. , 2010, The New England journal of medicine.

[19]  Sven Bergmann,et al.  Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. , 2010, Gastroenterology.

[20]  Jacques Fellay,et al.  ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C , 2010, Nature.

[21]  V. Soriano,et al.  Plasma Ribavirin Trough Concentrations at Week 4 Predict Hepatitis C Virus (HCV) Relapse in HIV-HCV-Coinfected Patients Treated for Chronic Hepatitis C , 2010, Antimicrobial Agents and Chemotherapy.

[22]  Jean-Michel Pawlotsky,et al.  Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. , 2009, The New England journal of medicine.

[23]  D. Breilh,et al.  Ribavirin plasma concentration predicts sustained virological response to peginterferon Alfa 2a plus ribavirin in previously treated HCV-HIV-coinfected patients. , 2009, Journal of acquired immune deficiency syndromes.

[24]  A. Koike,et al.  Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C , 2009, Nature Genetics.

[25]  Thomas Berg,et al.  IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy , 2009, Nature Genetics.

[26]  Jacques Fellay,et al.  Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance , 2009, Nature.

[27]  O. Weiland,et al.  50 ACTIVITY OF TELAPREVIR ALONE OR IN COMBINATION WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE 2 AND 3 HEPATITIS-C PATIENTS: INTERIM RESULTS OF STUDY C209 , 2009 .

[28]  V. Ratziu,et al.  10 RESULTS OF A PROOF OF CONCEPT STUDY (C210) OF TELAPREVIR MONOTHERAPY AND IN COMBINATION WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE 4 HCV PATIENTS , 2009 .

[29]  C. Pasquier,et al.  Serum concentrations of ribavirin and pegylated interferon and viral responses in patients infected with HIV and HCV , 2008, Journal of medical virology.

[30]  C. Costiniuk,et al.  Erythropoiesis-stimulating agent use for anemia induced by interferon-ribavirin treatment in patients with hepatitis C virus infection is not associated with increased rates of cardiovascular disease, thrombosis, malignancy, or death. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[31]  Ming‐Lung Yu,et al.  Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: A randomized trial , 2008, Hepatology.

[32]  C. Trépo,et al.  Prediction of Sustained Virological Response by Ribavirin Plasma Concentration at Week 4 of Therapy in Hepatitis C virus Genotype 1 Patients , 2008, Antiviral therapy.

[33]  P. Marquet,et al.  Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C , 2008, Hepatology.

[34]  Z. Younossi,et al.  A phase II dose finding study of darbepoetin alpha and filgrastim for the management of anaemia and neutropenia in chronic hepatitis C treatment , 2008, Journal of viral hepatitis.

[35]  M. Sherman,et al.  Clinical trial: exposure to ribavirin predicts EVR and SVR in patients with HCV genotype 1 infection treated with peginterferon alfa‐2a plus ribavirin , 2008, Alimentary pharmacology & therapeutics.

[36]  G. di Perri,et al.  The use of trough ribavirin concentration to predict sustained virological response and haematological toxicity in HIV/HCV-co-infected patients treated with ribavirin and pegylated interferon. , 2008, The Journal of antimicrobial chemotherapy.

[37]  B. Alobeid,et al.  Anti‐erythropoietin antibody–mediated pure red cell aplasia in a living donor liver transplant recipient treated for hepatitis C virus , 2007, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[38]  S. Sauleda,et al.  Early Monitoring of Ribavirin Serum Concentration is not Useful to Optimize Hepatitis C Virus treatment in HIV-Coinfected Patients , 2007, Antiviral therapy.

[39]  Tara L. Kieffer,et al.  Telaprevir and pegylated interferon–alpha‐2a inhibit wild‐type and resistant genotype 1 hepatitis C virus replication in patients , 2007, Hepatology.

[40]  Tara L. Kieffer,et al.  Antiviral activity of telaprevir (VX‐950) and peginterferon alfa‐2a in patients with hepatitis C , 2007, Hepatology.

[41]  R. Stravitz,et al.  Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha , 2007, Hepatology.

[42]  Tara L. Kieffer,et al.  Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. , 2007, Gastroenterology.

[43]  T. Asselah,et al.  Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin. , 2006, Gastroenterology.

[44]  R. Stauber,et al.  Ribavirin Levels and Haemoglobin Decline in Early Virological Responders and Non-Responders to Hepatitis C Virus Combination Therapy , 2006, Pharmacology.

[45]  S. Pol,et al.  The Impact of Haematopoietic Growth Factors on the Management and Efficacy of Antiviral Treatment in Patients with Hepatitis C Virus , 2005, Antiviral therapy.

[46]  A. Sanyal,et al.  Antibody-Mediated Pure Red Cell Aplasia Due to Epoetin Alfa During Antiviral Therapy of Chronic Hepatitis C , 2005, The American Journal of Gastroenterology.

[47]  Yoshiyuki Suzuki,et al.  Significance of Serum Ribavirin Concentration in Combination Therapy of Interferon and Ribavirin for Chronic Hepatitis C , 2005, Intervirology.

[48]  E. Keeffe,et al.  Erythropoietic Response to Anemia in Chronic Hepatitis C Patients Receiving Combination Pegylated Interferon/Ribavirin , 2005, The American Journal of Gastroenterology.

[49]  A. Bruchfeld,et al.  High‐dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C , 2005, Hepatology.

[50]  E. Schiff,et al.  Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. , 2004, Gastroenterology.

[51]  E. Bini,et al.  Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. , 2003 .

[52]  G. Bessard,et al.  Ribavirin Quantification in Combination Treatment of Chronic Hepatitis C , 2003, Antimicrobial Agents and Chemotherapy.

[53]  G. Hajian,et al.  Ribavirin dosing in chronic hepatitis C: Application of population pharmacokinetic‐pharmacodynamic models , 2002, Clinical pharmacology and therapeutics.

[54]  Dieter Häussinger,et al.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. , 2002, The New England journal of medicine.

[55]  R. Bruno,et al.  Premature discontinuation of interferon plus ribavirin for adverse effects: a multicentre survey in ‘real world’ patients with chronic hepatitis C , 2002, Alimentary pharmacology & therapeutics.

[56]  M. Peck-Radosavljevic,et al.  Rapid suppression of hematopoiesis by standard or pegylated interferon-alpha. , 2002, Gastroenterology.

[57]  Kenneth Koury,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[58]  G. Hajian,et al.  Population Pharmacokinetic and Pharmacodynamic Analysis of Ribavirin in Patients With Chronic Hepatitis C , 2000, Therapeutic drug monitoring.

[59]  G. Fattovich,et al.  Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: Role of membrane oxidative damage , 2000, Hepatology.

[60]  H. Conjeevaram,et al.  Ribavirin as Therapy for Chronic Hepatitis C , 1995, Annals of Internal Medicine.

[61]  J. Garson,et al.  A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. , 1994, Gastroenterology.

[62]  D. Ge,et al.  HEPATITIS C TRIALS THAT COMBINE INVESTIGATIONAL AGENTS WITH PEGYLATED-INTERFERON-alpha SHOULD BE STRATIFIED BY IL28B GENOTYPE , 2010 .

[63]  D. Harnois.  Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection , 2009 .

[64]  S. Zeuzem,et al.  Pegylated interferon monotherapy for chronic hepatitis C. , 2004, Seminars in liver disease (Print).

[65]  Thomas R. Riley,et al.  A Randomized Double-blind Placebo-controlled Trial , 2004 .

[66]  H. Conjeevaram,et al.  Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. , 1995, Annals of internal medicine.